SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Edwards today presented new data at New York Valves 2026 supporting its transcatheter aortic valve replacement (TAVR) ...
LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...
Edwards Lifesciences Corp. revealed excellent one-year data highlighting the performance of its newest generation Sapien 3 Ultra Resilia valve. Patients treated with the transcatheter aortic valve ...
The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe aortic stenosis without ...
Edwards TAVR data has a strong showing at NY Valves 2026 amid intense industry competition from Abbott Laboratories and Medtronic.
Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...
Last month, Edwards Lifesciences recalled its SAPIEN 3 Ultra Delivery System after reports of burst balloons during implantation, resulting in significant difficulty retrieving the valve into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results